文献速递间质性肺疾病肺结节与肺癌

三周与六周糖皮质激素治疗轻度免疫相关性肺炎的随机试验

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

本研究为随机试验,纳入106例轻度(CTCAE 1-2级)免疫检查点抑制剂相关肺炎患者,比较3周与6周糖皮质激素减量方案。结论支持6周方案作为标准治疗。

要点

  • 6周糖皮质激素方案是轻度免疫相关性肺炎的循证标准治疗。
  • 3周方案未达到非劣效性,8周治疗成功率低于6周方案。

核心结论

  • 本研究确立6周糖皮质激素方案作为治疗ICI相关肺炎的循证标准。

研究设计与样本

  • 随机试验,纳入106例轻度(CTCAE 1-2级)免疫检查点抑制剂相关肺炎患者,随机分配至3周或6周糖皮质激素方案。
  • 中位年龄72岁,2级患者占73%。

主要发现

  • 3级及以上不良事件发生率3周组12%、6周组24%,均可通过临床干预管理。
  • King's Brief间质性肺疾病评分较基线平均变化3周组4.78、6周组6.28(组间差异-1.50个百分点,95%CI -5.91至2.91)。

关键数值与推荐

  • 主要终点为8周治疗成功率,定义为静息室内空气SpO2≥90%且未因肺炎恶化而升级或延长激素治疗。

临床怎么用

  • 对轻度ICI相关肺炎,应优先选择6周糖皮质激素减量方案而非3周方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Optimal corticosteroid treatment duration for immune checkpoint inhibitor (ICI)-related pneumonitis remains uncertain. No randomized trials have addressed this issue. OBJECTIVES: To determine whether a 3-week corticosteroid taper is noninferior to the guideline-recommended 6-week taper for short-term treatment success in patients with mild (Common Terminology Criteria for Adverse Events grade 1-2) immune-related pneumonitis. METHODS: Patients with mild immune-related pneumonitis were assigned to either a 3-week or 6-week corticosteroid regimen. The primary endpoint was the treatment success rate at 8 weeks, defined as resting room-air SpO2 ≥ 90% without steroid escalation or prolongation due to pneumonitis worsening. MEASUREMENTS AND MAIN RESULTS: Overall, 106 patients were randomly assigned (median age = 72 years; grade 2, 73%). Treatment success rates were 66.7% and 85.2% in the 3- and 6-week groups, respectively, which did not demonstrate noninferiority (difference = -18.5 percentage points; 80% CI, -29.0% to -7.9%; P = .621) of the 3-week regimen. A predefined exploratory analysis indicated superiority of the 6-week regimen (P = .013). Grade ≥3 adverse events occurred in 12% and 24% of the 3- and 6-week groups, respectively; however, all were manageable with clinical interventions. The total quality of life mean change using the King's Brief Interstitial Lung Disease score from baseline was 4.78 and 6.28 in the 3- and 6-week groups, respectively (between-group difference = -1.50 percentage points; 95% confidence interval, -5.91 to 2.91). Overall survival was comparable between the groups (hazard ratio = 1.03; 95% CI, 0.46-2.29; P = .95). CONCLUSIONS: This study establishes the 6-week corticosteroid regimen as an evidence-based standard for treating ICI-related pneumonitis.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Fujimoto D, Abe M, Murotani K, et al. Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial. Am J Respir Crit Care Med. 2026. PMID: 42398004. doi:10.1093/ajrccm/aamag349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。